Henlix
As of the edition of 20 October 2026, Henlix runs 4 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Serplulimab | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Cancer: 3 trials led
- Digestive system: 1 trials led
- Infections: 1 trials led